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Background: Heavy drinking jeopardizes the health of patients in HIV primary care. In alcohol dependent patients
in HIV primary care, a technological enhancement of brief intervention, HealthCall administered via interactive voice
response (HealthCall-IVR) was effective at reducing heavy drinking. The smartphone offered a technology platform
to improve HealthCall.
Methods: Working with input from patients, technology experts, and HIV clinic personnel, we further developed
HealthCall, harnessing smartphone technological capacities (HealthCall-S). In a pilot study, we compared rates of
HealthCall-S daily use and drinking outcomes in 41 alcohol dependent HIV-infected patients with the 43 alcohol
dependent HIV-infected patients who used HealthCall-IVR in our previous efficacy study. Procedures, clinic,
personnel, and measures were largely the same in the two studies, and the two groups of patients were
demographically similar (~90% minority).
Results: Pilot patients used HealthCall-S a median of 85.0% of the 60 days of treatment, significantly greater than
the corresponding rate (63.8%) among comparison patients using HealthCall-IVR (p < .001). Mean end-of-treatment
drinks per drinking day was similar in the two groups. Patients were highly satisfied with HealthCall-S (i.e., 92%
reported that they liked using HealthCall-S).
Conclusions: Among alcohol dependent patients in HIV primary care, HealthCall delivered via smartphone is
feasible, obtains better patient engagement than HealthCall-IVR, and is associated with decreased drinking. In HIV
primary care settings, HealthCall-S may offer a way to improve drinking outcomes after brief intervention by extending
patient engagement with little additional demands on staff time.
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Alcohol has been termed “the forgotten drug” in the HIV
epidemic [1] and heavy or hazardous drinking is import-
ant to target in improving the health and survival of those
infected with HIV [2]. Heavy drinking is associated with
poor antiretroviral (ART) adherence [3-5], is a leading
cause of morbidity and mortality [6-10] among those with
liver disease, and is a clinical challenge for those with HIV
[11,12]. Despite calls to address this [8,13-16], heavy
drinking remains prevalent in HIV clinic settings [13,15],* Correspondence: dsh2@columbia.edu
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reproduction in any medium, provided the orwhere resources for interventions are often limited [17-19].
Recommendations to refer patients to outside treatment
[11,20] do not solve this, since patients seldom follow re-
ferrals [21,22]. Feasible, scalable drinking-reduction inter-
ventions for use within the HIV clinic are needed.
Trials in HIV populations [23-27] show that some in-
terventions are effective for drinking-reduction [25-27].
However, their length (6–15 sessions, 540–1350 min),
limits dissemination potential. In general primary care
patients with hazardous, non-dependent drinking, brief
interventions are effective (from structured advice to well-
supervised motivational interviewing [MI]) [22,28-34].
However, primary care patients with severe drinking prob-
lems need more extensive intervention [22,34-36]. Thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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unrealistically increasing staff time.
User-friendly mobile technologies can extend patient
involvement without greatly increasing staff time. Using
interactive voice response (IVR) technology, we devel-
oped the initial version of “HealthCall” [35-37] to extend
HIV patient involvement after a brief drinking-reduction
intervention. HealthCall is explained to the patient at
the end of the brief session. HealthCall has two main
components, each delivering an evidence-based change
technique (Figure 1).
(1)Component 1 delivers self-monitoring. Patients self-
monitor drinking for 60 days by answering brief
(2–4 min) automated questions about drinking and
other general and HIV behaviors, and receive
reinforcement for doing so (e.g., “We’re glad you
called”). Patients’ answers go into a database.
Meta-analysis indicates that self-monitoring is a
key contributor to the effectiveness of brief
intervention [38].
(2)Component 2 delivers personalized feedback, also
shown by meta-analysis to be an important element
in behavior change [39,40]. At 30 and 60 days, a
graph of the patient’s drinking and summary of other
self-monitoring data is presented to the patient by
the staff member. This forms the basis of a 10–15 -
minute discussion, identifying patterns and planning
for ways to improve. Incorporation of an in-person
meeting is consistent with participants’ preference for
technology-based interventions that are combined
with interpersonal support [41], and with a meta-
analysis indicating that interventions involving someFigure 1 The two components of HealthCall.personal contact are more effective than interventions
that are entirely electronically delivered [42].
To reduce hazardous drinking in patients in urban HIV
primary care, we tested HealthCall on the IVR platform
(HealthCall-IVR) in a large randomized trial [35], compar-
ing MI +HealthCall-IVR to MI-only and a time-matched
educational control. Patients in MI +HealthCall-IVR made
a median of 64.4% of the 60 HealthCall daily calls. At the
end of treatment, drinking was significantly lower in MI +
HealthCall-IVR than MI-only or control, with results en-
tirely concentrated within alcohol dependent patients [35].
The trial showed that HealthCall successfully enhanced
brief drinking-reduction intervention among alcohol
dependent patients in HIV primary care, while suggesting
room for improved engagement in daily self-monitoring.
Smartphone costs are decreasing and use is increasing
rapidly [43,44], suggesting that the diffusion of smart-
phone technology can provide widespread, engaging
HIV interventions [45]. For HealthCall, compared to
IVR, smartphone technology has three main advantages
to engage patients: 1) visuals and graphics: the screen can
offer images, including graphics and a video of a friendly
counselor delivering greetings, questions, reinforcement,
and suggestions. The visual aspects seemed likely to help
engage cognitively impaired patients. (Cognitive deficits
are associated with alcohol dependence, greater viral load
[46-48] and treatment dropout [49,50], so cognitive con-
siderations underlie our HealthCall work); 2) accessibility
and connectivity: HealthCall on the smartphone (Health-
Call-S) offers immediate access any time, regardless of
telephone or internet availability; 3) more nuanced inter-
activity: due to the greater smartphone computing
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complex patterns of questions or statements more closely
corresponding to patients’ answers to previous questions.
Given these advantages, we conducted a pilot study to
adapt HealthCall for delivery via on the smartphone
(HealthCall-S) among alcohol dependent patients in HIV
primary care, and determine HealthCall-S feasibility in
terms of patient engagement, drinking reduction, and re-
actions. To maximize the information about HealthCall-S
with the resources available, we used Android smart-
phones and conducted a single-arm study of HealthCall-S.
To place the results in context, we compared HealthCall-S
results on patient engagement and drinking reduction to
results we previously obtained using HealthCall-IVR in
HIV alcohol dependent patients at the same clinic, who
served as a historical comparison group (hereafter, “com-
parison group”). The comparison group consisted of the
alcohol dependent patients in the MI +HealthCall-IVR
arm of our previous randomized trial [35]. Aside from a
pilot study requirement that patients meet criteria for al-
cohol dependence and the fact that we provided each pa-
tient with an Android smartphone, the setting, other
eligibility criteria, drinking measures, and study proce-




We obtained patient and HIV health educator-counselor
input throughout this process to create a more engaging,
user-friendly patient procedure. All patients giving input
were minority individuals with alcohol or drug abuse
treated at the urban HIV primary care clinic where we
conducted our studies. We used the Android rather than
iPhone platform because Android is less expensive.
Stage 1
A bilingual MI + HealthCall counselor conducted indi-
vidual interviews with five patients who previously used
HealthCall-IVR to ask general reactions to HealthCall
for the smartphone, and to specific ideas for changes.
Patients responded favorably, and made suggestions (e.g.,
more personalization, variation to make calls more inter-
esting, adding a convenient way to request discussion with
the counselor).
Stage 2
Using these and other ideas gained from the original
randomized trial, a draft of the HealthCall-S daily script
was prepared, using the HealthCall-IVR script as a start-
ing point. Changes included new questions and state-
ments for a video counselor, graphic images to illustrate
statements and questions, and greater personalization to
patients’ responses.Stage 3
In a focus group, five previous HealthCall-IVR partici-
pants gave their reactions to specific aspects of the
script. Topics included preference for real or animated
video counselor (video preferred by all), interest in a
graph of drinking over the prior seven days (4 of 5 pa-
tients wanted this, and suggested making it optional),
preferences for different images, and question wording.
This information was used to refine the script.
Stage 4
The research team worked with Andriod programmers
on how to use smartphone capacities to implement the
script in the most user-friendly, engaging way. The script
was further developed collaboratively with the program-
ming experts and HIV health educators who worked on
HealthCall studies.
Stage 5
Video portions of the script were produced (versions in
English and Spanish), with a bi-lingual counselor as the
actress. These were edited via collaboration between the
research team, programming experts, and the medical
center media department.
Stage 6
Consulting closely with the research team, the program-
mers prepared a beta version of HealthCall-S, integrating
the images, video, and an oversized keypad for easy
entry of patient responses. The research team then ex-
tensively pre-tested of the beta version, which was de-
bugged by the programmers.
Stage 7
A counselor conducted individual interviews with six
previous participants in HealthCall studies to obtain de-
tailed reactions to each component of HealthCall-S.
Based on these reactions, the research staff made final
adjustments to the HealthCall-S script, which were im-
plemented by the programmers.
Pilot study procedures
Pilot study patients were recruited from a large urban
HIV primary care clinic. Eligibility included ≥4 drinks of
alcohol at least once in the prior 30 days; current DSM-
IV alcohol dependence; English- or Spanish-speaking;
≥18 years; not actively psychotic, suicidal, homicidal, or
grossly cognitively impaired; and not a participant in the
prior randomized trial [35]. Clinic staff routinely asked
all patients an electronic chart question about current
drinking, and referred patients likely to meet the drinking
threshold to the bilingual counselors for eligibility assess-
ment and screening, informed consent, assessment, and
intervention in English or Spanish. Between June 2012
N = 96
Referred by clinic staff to study staff for pre-screening 
Excluded after enrollment 
Withdrew consent (N=1)
Withdrawn due to medical condition (N=1)
N= 37
Provided 60-day data (2 lost to follow-up)
N= 36 
Offered an additional 30 days of participation (one patient 
planning to leave NYC at 60 days not offered continuation)
N=23
Wished to continue and provided 90-day data
N = 56b
Pre-screened and found to be eligible for full screening: 
positive for ≥4 drinks, ≥1 day, past 30 days and current 
DSM-IV alcohol dependence (rated by counselor on 
checklist)
N= 41c
Fully screened (N=41 given available time and resources), 
found to be eligible for enrollment, enrolled in study. 
Figure 2 Flowchart of pilot study participants a. aStudy of
HealthCall-Smartphone (HealthCall-S) enhancement of Motivational
Interviewing for drinking reduction: New York City HIV primary care
alcohol dependent patients at baseline; patients enrolled June 2012-
July 2012. bDrinking eligibility (≥4 drinks, ≥1 day, past 30 days)
identical to the previous 3-arm MI + Healthcall-IVR randomized trial
[35]; alcohol dependence an additional eligibility requirement. c Other
eligibility requirements included absence of psychosis, being actively
suicidal or homicidal, severely cognitive impaired using Halstead-Reitan
Trails A. These requirements were identical to the previous 3-arm MI +
Healthcall-IVR randomized trial [35].
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gibility, using a paper-and-pencil checklist that covered (a)
occasions of ≥4 drinks of alcohol in the prior 30 days and
(b) current DSM-IV alcohol dependence criteria. Of these,
56 patients passed the pre-screen procedures. Of the 56,
41 patients were fully screened, including counselor ad-
ministration of the Halstead-Reitan Trials A test [51], and
counselor computer-assisted psychosis items from the
Structured Clinical Interview for DSM-IV (SCID; [52]),
suicide and homicide items from the Addiction Severity
Index [53], and DSM-IV alcohol dependence items from
the NIAAA Alcohol Use Disorders and Associated Dis-
abilities Interview Schedule (AUDADIS-IV), a reliable and
valid diagnostic procedure in the general population and
in English- and Spanish-speaking substance abuse and pri-
mary care patients [54-56]. Counselors also cross-checked
patients’ clinic charts for evidence of psychosis, suicidality,
or homicidality. All 41 of the fully screened patients were
found to be eligible, completed a full assessment battery
(see below) and entered into the pilot study (Figure 2).
Due to organizational constraints (ending of a clinic sub-
contract), we did not conduct formal eligibility screening
of the remaining 15 patients.
Comparison group procedures
Comparison group patients were recruited earlier for the
randomized trial [35] from the same clinic, by the same
coordinator, with the same procedures and eligibility cri-
teria, with one exception: alcohol dependence was not
an eligibility requirement in that study, so the alcohol
dependence pre-screening procedures were not employed.
In that study, the identical A-CASI method was used to
assess DSM-IV alcohol dependence criteria among all pa-
tients entered. Patients in the MI +HealthCall-IVR arm
who met criteria for DSM-IV alcohol dependence consti-
tuted the comparison group (N = 43).
Patients in both studies were assessed at baseline, re-
ceived a 20–25 min MI, were instructed in HealthCall
use, told that it might help them reduce their drinking,
asked to use HealthCall for 60 days, and asked to return
for assessment and brief counselor meetings at 30 and
60 days. To explore HealthCall-S over a longer period,
pilot study patients were offered 30 more days of partici-
pation at 60 days. Columbia University and Mt. Sinai
Medical Center IRBs approved all procedures.
Assessments
During treatment, measures were administered (in English
or Spanish) prior to the brief counselor meetings, using
audio computer-assisted self-interviews (A-CASI). Alcohol
consumption was assessed with A-CASI 30-day TimeLine
FollowBacks (TLFB) [57].
We measured patient perceptions and satisfaction with
HealthCall-S participation with a set of 12 items wedesigned to tap reactions to specific aspects of HealthCall-
S. Three- or five-level Likert-type items covered such as-
pects as patients’ feelings of safety and privacy using
HealthCall-S, whether it affected their memory and under-
standing of their drinking patterns, motivation and self-
confidence in drinking reduction efforts, and whether it
reminded them of their drinking goal and initial counselor
meeting. Patients self-administered these questions after
their final meeting with their counselor. Responses were
grouped into three levels across all items for ease of
interpretation.
Outcomes
The primary drinking outcome for both studies was
mean number of drinks per drinking day in the prior 30
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selected due to the potential for liver toxicity and dam-
age from large alcohol quantities. A secondary outcome
was percent days abstinent (PDA) over the prior 30
days.
Motivational interview
At baseline, counselors administered a 20–25 minute
individual MI session using standard techniques to mo-
tivate drinking reduction. In the pilot study, three coun-
selors administered the interventions. All had prior
experience as HIV health educators, but not as alcohol-
ism counselors. The first two were the MI + HealthCall
counselors in the three-arm randomized trial; the third
administered MI + HealthCall in a similar study on non-
injection drug use [37]. Counselors also gave all patients
a NIAAA drinking reduction pamphlet [58].Table 1 HealthCall-Smartphone script for daily self-monitorin
Content of statement or question P
1. Friendly welcome greeting that varies by daya R
2. Request to enter password E
3. Statement that questions are about yesterday (morning, afternoon,
evening or during the night)
S
4. Number of drinks of beer, wine, liquora,b? S
6
5. How much wanted to drink? S




7. Thought about pros and cons of drinkingb? (yes/no) R
8. Thought about drinking reduction goalb? (yes/no) R
9. How important was drinking reduction?
10. How committed to drinking reduction?
11. IF DRANK: Reasons for drinkinga (yes/no to nine reasons, e.g.,




12. IF DID NOT DRINK: Reasons for not drinkinga (yes/no to nine
reasons, e.g., my health; made commitment not to; no money for
alcohol; feel good when do something positive for self)?
M
13. Statement praising abstinence or meeting drinking goal (4 rotated,
different statements), or continuing to call even if goals weren’t meta
I
u
14. Statement of one of 30 daily “tips” in random order (suggestions
on how to cut down drinking or maintain abstinence)a
S
N
15. Drug use? I
16. If on ART, were all HIV meds taken? S
17. If had sex, was it protectedb? S
18. Felt well physically? Stressed? Angry? sad/depressed? how was day
overall? (5 yes/no questions)b
I
c
19. If reported at-risk drinking, counselor call offered via one-touch link
to counselor’s phone/voicemaila
P
20. Outgoing tailored goodbye (15 versions) R
w
aquestion or statement via video of the counselor (others heard and accompanied
baccompanied by visual image (photo or drawing) on the screen.HealthCall-S Component 1: Self-Monitoring
An abbreviated version of the HealthCall-S script is
shown in Table 1. As shown, the script included a wel-
coming greeting, questions about quantities of beer,
wine and liquor, desire (craving) to drink, whether the
patient thought about pros and cons of drinking or his/
her drinking goal, the importance of drinking reduction
and commitment to this, reasons for drinking or not
drinking, a statement praising/reinforcing drinking re-
duction or continued calling, drug use, use of antiretro-
viral medication, safe sex, how the patient felt mentally
and physically, an offer to see a graph showing the last
seven days of drinking, an offer to speak with the
counselor, a tip to reduce drinking that varied daily, and
a goodbye that had 15 variations.
After the MI session, counselors provided patients
with an Android smartphone, explained the purpose andg calls
urpose
einforce HealthCall-S use; add variety to daily script
nsure privacy
tandardize timeframe regardless of when HealthCall-S is used
elf-monitor drinking to increase self-awareness; provide data for 30- and
0-day personalized feedback
elf-monitor craving to increase self-awareness
elf-monitor progress to increase self-awareness (optional because not all
atients wish to see the graph every day)
emind patient of MI session to maintain or increase motivation to change
emind patient of MI goal to maintain or increase motivation to change
dentify drinking motives and triggers (internal and social-contextual)
o increase self-awareness, provide data for 30- and 60-day personalized
eedback
aintain or increase self-efficacy and motivation to change
ncrease motivation and self-efficacy; reinforce continued HealthCall-S
se; add variety to daily script
uggest skills to patients for cutting down or staying abstinent based
IAAA evidence-based materials; also to add variety to daily script
dentify potential substitute substance use pattern
elf-monitoring of ART; identify if alcohol and ART adherence are linked
elf-monitoring of sexual risk behaviors
ncrease self-awareness; identify drinking triggers and patterns; show
oncern for the whole person
rovide counselor assistance if wished
einforce HealthCall-S use based on patients’ input and date/day of the
eek/weekend; add variety.
by text on screen).
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HealthCall-S on the smartphone for the first time to en-
sure its correct use. A good time for daily use was iden-
tified with the patient, and the smartphone alarm set to
this time. To start HealthCall-S, patients touched an
icon on the smartphone home screen and entered a self-
selected password. They input responses on a screen
touchpad with numbers enlarged for easier use.
HealthCall-S stored patient input on the smartphone,
enabling HealthCall-S use regardless of network con-
nectivity. Responses were transmitted securely to an
online server. The database was checked daily for trans-
mitted data. If no data were received for two consecutive
days, counselors contacted patients to remind them to
continue using HealthCall.
HealthCall-S Component 2: Personalized feedback
Daily drinking self-monitoring data were used to pro-
duce personalized feedback in the form of a graph show-
ing the number of drinks reported daily against the
patient’s drinking goal, and summary statistics (average
drinks per drinking day; reasons for drinking). After 30
days, counselors met with patients, presented their 1–
30 day graph and summary, ensured that they understood
it, and used it as the basis for a 10–15 minute discussion
of the patient’s drinking. This included identifying pat-
terns, and planning ways to maintain gains or improve.
Counselors reinforced drinking reduction and change ef-
forts. Counselors then re-set the drinking goal if patients
wished, suggested HealthCall-S use for 30 more days, and
scheduled a 60-day meeting. At 60 days, a similar discus-
sion focused on the 31–60 day graph and summary. Pilot
patients were offered HealthCall-S use for 30 more days.
For those not wishing to continue, the counselor con-
ducted brief termination planning (e.g., encouraging con-
tinued self-monitoring). For patients who continued, these
procedures were followed 30 more days.
HealthCall-IVR: comparison group
As described previously [35], self-monitoring was delivered
via similar questions on a telephone automated IVR sys-
tem. Personalized feedback was delivered in an earlier ver-
sion of the graph and summary, in a similar meeting with
the counselor. HealthCall-IVR participation was 60 days,
with assessment-only visits at 90 days and subsequently.
Training, quality control, supervision
A MI Network Trainer (MINT) trained the counselors
on MI, giving a refresher course before the pilot study,
and made fidelity ratings [59] of six pilot study MI ses-
sions, two for each counselor. These showed good to ex-
cellent fidelity across domains, e.g., mean % complex
reflections (57.4%), MI spirit/empathy (4.3; 4.0), and num-
ber of MI non-adherent statements (0.0). Similar MIfidelity was reported in the three-arm trial [35]. HealthCall
procedures were manualized. In both studies, E.A. super-
vised the counselors weekly on clinical and administrative
procedures. No counselor effects on treatment outcome
have been detected in any HealthCall studies [35-37].
Compensation
In the pilot study, patients received a $25 gift certificate at
baseline, 30 days, and (if they continued) 90 days. At 60
days, those who terminated received a $40 gift certificate
and the smartphone or a $100 gift certificate; continuing
patients received a $40 gift certificate. The option to keep
the phone or receive a $100 gift certificate was also given
at 90 days; its purpose was to discourage sale or loss of
the phone during the study. Compensation in the three-
arm trial was $20 in gift certificates at each visit up to 90
days. To improve dissemination potential, compensation
was not linked to level of HealthCall use.
Analysis
To compare the two treatment conditions on demographic
characteristics, call rates, and dropout rates, chi-square
tests were used for categorical variables and Wilcoxon
non-parametric tests for non-normally distributed con-
tinuous and count variables. Additional generalized linear
models that controlled for demographic variables, number
of DSM-IV dependence criteria, and number of years since
HIV diagnosis were used to additionally test for treatment
differences in call rates. To compare NumDD at 60 days in
the HealthCall-S and HealthCall-IVR groups, we used a
generalized linear model with a negative binomial distribu-
tion (PROC GENMOD, SAS), consistent with the method
used to examine treatment effects in the three-arm trial.
We also explored PDA at 60 days using the same method.
All generalized linear models included any participant who
provided at least baseline information. The models con-
trolled for baseline number of DSM-IV dependence cri-
teria and number of years since HIV diagnosis, since these
differed significantly between the pilot study and compari-
son groups. Parameter estimates and associated p-values
were used to indicate differences between the two condi-
tions. All tests were two tailed: p < 0.05 indicated statistical
significance. For the 12 items measuring patient percep-
tions of and satisfaction with HealthCall-S procedures, we
present information descriptively.
Results
Participants in the pilot study and comparison group
Of the 41 patients entered into the pilot study (Figure 1),
one withdrew (lack of interest) and one was withdrawn
(medical condition precluded further participation). Of
the 39 remaining patients, 37 remained in the study for
at least 60 days and provided 60-day outcome data (25
on time, 12 after the 60 day point). Of these, all but one
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meeting were offered an additional 30 days of interven-
tion; 23 continued for 90 days. Most patients in the pilot
study and comparison group were male (71.8% and
81.4%, respectively) and minority (87.1% and 93.1%, re-
spectively); relatively few were employed or in stable re-
lationships (Table 2). Mean baseline drinks per drinking
day (NumDD) was high in both groups. Of the charac-
teristics in Table 2, the samples differed in terms of stat-
istical significance on two characteristics: years since
HIV diagnosis (more years in the comparison group)
and dependence severity (number of DSM-IV criteria,
greater in the pilot study group).Exposure to HealthCall-S (pilot study) and HealthCall-IVR
(comparison group)
From 1–60 days, pilot patients used HealthCall-S a me-
dian of 85.0% of the days, compared to 63.8% of the days
in the HealthCall-IVR comparison group, a 33% differ-

















Antisocial personality disorder 1
Beck depression inventory ≥17, indicating clinical depression 0
Continuous variablesb M
Age, years 4
Years since HIV diagnosis 1
Drinks per drinking day (NumDD) 9
Percent days abstinent (PDA) 5
DSM-IV dependence criteria count 5
Beck Depression Inventory 7
agroup differences tested with chi-square.
bgroup differences tested with Kruskal Wallis test.After controlling for demographic variables, preferred
language, years since HIV diagnosis, and DSM-IV alco-
hol dependence criteria count, this difference between
pilot and comparison daily use remained statistically sig-
nificant (X2 = 17.66, NumeratorDF = 1, DenominatorDF =
69, p < 0.001). In the pilot study group, use of HealthCall
was similar across patient characteristics, with no signifi-
cant or clinically meaningful differences found by sex,
age, race, education level, marital status, language of par-
ticipation (English or Spanish), employment status, years
since HIV diagnosis, and alcohol severity.Retention in treatment: pilot study and comparison
group patients
Treatment retention was excellent. In patients using
HealthCall-S, 5.1% dropped out by 60 days, while 11.6%
of the comparison patients using HealthCall-IVR
dropped out by that point (Fisher’s exact test p = 0.44).
Although not meeting the threshold for statistical sig-
nificance, results did favor HealthCall-S.mparison group
I + HealthCall-S MI + HealthCall-IVR p-level
ilot study Comparison group














ean (s.d.) Mean (s.d.)
5.5 (11.5) 46.0 (7.2) 0.51
1.5 (8.4) 14.9 (7.4) 0.04
.3 (6.9) 8.1 (3.9) 0.84
8.1 (27.4) 61.3 (24.2) 0.81
.8 (1.1) 4.9 (1.7) 0.03
.5 (6.9) 5.3 (5.9) 0.18
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(pilot study patients)
We examined whether any characteristics in Table 1 pre-
dicted stopping at 60 days; no statistically significant or
otherwise clinically meaningful relationships were found.
Change in drinking: HealthCall-S (pilot study) and
HealthCall-IVR (comparison group)
Among the pilot study patients, baseline mean NumDD
was 9.3, dropping to 3.9 at 60 days, similar to the reduc-
tion in the comparison group (8.1 at baseline, 3.5 at 60
days). Among the pilot patients who continued an extra
30 days, mean NumDD was 2.99 at 90 days; mean
NumDD in the comparison group at their post-
treatment 90-day assessment was 4.04. PDA in the pilot
study patients at baseline and 60 days (58.1%; 79.2%)
was similar to PDA in the comparison group (61.3%;
82.1%). End-of-treatment 30-day abstention was 25.6%
in pilot study patients versus 16.3% of the comparison
group, not significant but favoring HealthCall-S.
Pilot study patient perceptions of and satisfaction with
HealthCall-S participation
As shown in Table 3, a substantial majority of pilot pa-
tients felt that HealthCall-S participation reminded them
of their drinking goal and initial meeting with their
counselor. Nearly all patients liked using HealthCall-S
and felt their responses were safe, although slightly over
1/3 nevertheless had some concerns about privacy. Just
over half the patients were surprised by their drinking
pattern as shown in the 30-day graph. A large majority
felt that HealthCall-S participation helped them remem-
ber and understand their drinking patterns, and that it
increased their motivation and self-efficacy regarding
drinking reduction. Of the 30 daily suggestions onTable 3 Patient feedback on HealthCall-S procedures at end o
Always
Reminded them of drinking goal 86.49
Reminded them of initial meeting with counselor 67.57
Agree
Felt HealthCall-S responses were safe 94.59
Concerns about privacy using Healthcall-S 37.84
Liked using Healthcall-S 91.89
Surprised by the drinking pattern shown in 30-day graph 56.76
Helped remember drinking quantity, frequency 83.78
Helped understand drinking quantity, frequency 91.89
Increased motivation to reduce drinking 81.08
Increased confidence could reduce drinking 83.33
HealthCall graph increased interest in HealthCall-S 86.49
HealthCall graph increased perceived benefit of HealthCall-S 91.89cutting down drinking or maintaining abstinence (as
noted in Table 1, Row 14; data available on request), 15
were rated helpful/very helpful by over two-thirds of the
patients, and 13 were rated helpful/very helpful by over
half the patients.
In the comparison group, we did not obtain quantita-
tive data on patient reactions, but rather, conducted brief
unstructured discussions with patients at the end of their
60-day meeting. While most said HealthCall was easy to
use and helpful in increasing awareness of drinking and
triggers, the most common suggestion was the need to
introduce variety in the calls to reduce repetitiveness, in-
formation that shaped HealthCall-S development.
Discussion
The primary aim of the pilot study was to determine the
feasibility and acceptability of HealthCall for the smart-
phone (HealthCall-S) after a brief drinking-reduction
motivational interview in alcohol dependent, minority
HIV-infected patients. This study was conducted in a
real-world, urban HIV primary care setting. Through 60
days of treatment, the high engagement and retention
rate suggests that HealthCall-S was very acceptable to
these patients. Further, the statistically significant differ-
ence between use rates in the pilot study and comparison
group suggests better patient engagement in HealthCall-S
than HealthCall-IVR. Further, post-intervention patient
responses regarding satisfaction with HealthCall-S not
only indicated that HealthCall-S participation was a posi-
tive experience, but suggested that it strengthened self-
awareness, motivation and self-efficacy, the elements we
wished to reinforce through HealthCall-S. Given the risk
heavy drinking poses to the health and survival of HIV al-
cohol dependent patients and the lack of sustainable inter-
ventions for them, the pilot study offers promise for anf final appointment
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time and resources to administer.
In patients using HealthCall-IVR or HealthCall-S,
drinking decreased from baseline to 30 days, and then
decreased further between 31 and 60 days. The further
decreases contrasted with drinking between 31–60 day
drinking in the other arms of the randomized trial, in
which drinking stayed flat (MI-only) or rebounded (at-
tentional control). The 31- to 60-day decreases among
patients using HealthCall is consistent with a random-
ized pilot study comparing MI + HealthCall-IVR to MI-
only targeting drug use among HIV-infected patients
[37]. These similarities suggest that HealthCall effects
generalize across platforms and substances. Patients in
MI-only arms also met with counselors but had no self-
monitoring data to review. We therefore attribute the
continued 31-to-60 day decline to the personalized feed-
back based on self-monitoring data and its discussion at
30 days, which may provide patients and counselors with
a more accurate picture of the prior 30 days than patient
retrospective recall, allowing for more valid planning
about maintaining gains and achieving further progress.
Healthcall is theorized to work by increasing: (1)
drinking awareness through self-monitoring; (2) com-
mitment to change; and (3) self-efficacy [35]. Patients’
subjective reactions after participating in MI + Health-
Call-S suggested that HealthCall-S was helpful through
these mechanisms. However, to formally determine
whether HealthCall effects are mediated through these
constructs, they must be measured before and after
HealthCall-S participation, and subjected to mediation
analysis. This should be done in future studies.
At 60 days, we offered an additional 30 days of
HealthCall-S participation to pilot study patients, of
whom 62% continued. These patients showed lower
drinking at 90 days than the comparison group, which
had an assessment-only visit at 90 days. Because pilot
study patients self-selected to continue, conclusions
about benefits of the extra 30 days cannot be drawn. In
our original proof-of-concept HealthCall pilot study
[36], only 48.4% of the patients wished to continue from
60 to 90 days, leading us to select 60 days as the Health-
Call “dose” for the 3-arm randomized drinking-reduction
trial. For further trials, 60 days appears to remain the best
duration to test, since a standardized treatment dose is
needed, and a 38% treatment dropout rate by 90 days
would bias results. In eventual clinical dissemination, pro-
viders and patients could adjust the HealthCall “dose”, in-
cluding longer duration if the patient needed and wished
to continue, “vacation” periods after stabilization of drink-
ing reduction, and resumption if needed.
Additional study limitations are noted. First, patients
were not randomly assigned to HealthCall-IVR or
HealthCall-S. Potential biases that can arise from thelack of random assignment include (a) a change in the
nature of patient population (demographic, clinical)
treated at the clinic between the periods in which the
HealthCall-IVR and HealthCall-S patients were studied;
(b) a difference in the nature of the alcohol disorders in
the two groups of patients; (c) a change in clinic man-
agement of the drinking outcome; or (d) a change in
clinic attitudes towards MI + HealthCall after the suc-
cessful outcome of the earlier randomized trial, leading
to changes in the nature of the patients referred by clinic
staff to the smartphone pilot study. As noted above, we
carefully examined the two groups on a wide range of
clinical and demographic factors. The two differences we
found, shorter time since HIV diagnosis and greater se-
verity of alcohol dependence in the pilot study group,
could have led to worse outcomes in the pilot study
sample. While we controlled for these two characteris-
tics in our analyses, results for the pilot patients might
have been understated due to their more serious prog-
nostic factors. Regarding clinic management of alcohol
dependence, this did not change during the two study
periods. Regarding clinic attitudes, over the course of
the original randomized trial, the clinic medical director
and staff become increasingly positive about patient par-
ticipation in our studies. However, other than the two
differences we detected between comparison and pilot
study patients (more recent HIV diagnosis and greater
alcohol dependence severity in the pilot study patients)
we know of no differences in the nature of patients re-
ferred to us across the course of that study, or differ-
ences between referrals in that study and the pilot study.
We do not consider the present study to provide the
same level of definitive information as a randomized
trial. However, for the preliminary goals of the present
pilot study, the similar or identical procedures, clinic,
eligibility criteria and their assessment, outcome as-
sessments, study personnel, and other patient charac-
teristics suggest that the HIV alcohol dependent
patients in MI + HealthCall-IVR were a reasonably in-
formative comparison group for the HealthCall-S pilot
patients.
A second limitation is that the pilot study did not in-
clude post-treatment follow-up. In the three-arm trial,
follow-ups were at 90 days, 6 months, and 12 months.
Exploring 12-month drinking data by HealthCall call
rates showed that alcohol dependent patients with call
rates at or above the median call rate drank less at 12
months (mean NumDD = 3.4, s.d. 1.4) than patients with
call rates below the median (mean NumDD = 4.9, s.d.
3.3). This difference, while not significant, is consistent
with better long-term drinking outcomes among HIV-
infected patients with higher HealthCall engagement. A
trial of HealthCall-S with post-intervention follow-up
would provide information about whether the higher
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nificantly better long-term outcomes.
A third limitation is that much of the content (ques-
tions and statements; Table 2) for the self-monitoring
component of HealthCall-S involves drinking. We do not
know whether this content contributed to HealthCall-S ef-
fects, or whether daily participation in questions and
statements on topics unrelated to alcohol would produce
a similar drinking-reduction effect. Determining this
would require a trial with a control condition involving
HealthCall questions and statements without alcohol con-
tent. Such a control condition would require compensat-
ing patients to participate, and it would not provide
information for the personalized feedback on drinking.
While such a control condition may be of interest to the-
oretical researchers, we have not undertaken it because (a)
the personalized drinking feedback is important, (b)
payment for any HealthCall daily self-monitoring partici-
pation defeats the purpose of developing a sustainable
intervention and (c) even if successful, a drinking-reduction
intervention with no drinking-related content would lack
face validity to patients and providers, limiting eventual
dissemination.
In the future, technologies may emerge offering fea-
tures even more advantageous than the smartphone.
The possibility of such developments does not detract
from the value of developing HealthCall-S and other
smartphone-based health interventions if the interven-
tions are based on theory that can be applied to technol-
ogy as it develops. We began with the automated IVR
platform for HealthCall because this technology was
available. What we learned from this work enabled us to
take the conceptual framework for HealthCall and apply
it to the technological capacities of the smartphone to
better engage patients.
A question of some interest is whether HealthCall-S is
effective among HIV alcohol dependent patients after
they receive a briefer drinking-reduction intervention
from clinical staff without specialized training. If so, this
would greatly expand the dissemination potential of
HealthCall-S, since carefully supervised motivational
interviewing, common in research studies but a rare
intervention among medical staff in community clinics,
would no longer be required.
While HealthCall-S could potentially be used to en-
hance brief intervention among patients in other med-
ical settings, we have worked with HIV-infected patients
because they are all ill with a disease for which the med-
ical consequences of heavy, dependent drinking are ser-
ious. Since the total amount of time patients are
involved with HealthCall is brief (20–25 minutes with a
counselor at baseline, a few minutes each day for
HealthCall, and 10–15 minutes with a counselor at 30
and 60 days), we have not attempted to simultaneouslyinfluence multiple HIV problems, since the possibility of
successfully influencing any health behavior is uncertain
if too many are targeted in the same brief intervention.
However, for alcohol dependent HIV-infected patients
with ART adherence problems that are clearly linked to
drinking, a joint approach after minor adaptations of
HealthCall-S could be successful and should be explored
in a new trial.
Conclusions
In summary, this pilot study showed significantly im-
proved patient engagement using HealthCall-S compared
to HealthCall-IVR, and considerable patient satisfaction.
Results confirm that HealthCall-S is feasible, suggest
that it is as effective as HealthCall-IVR in the short-
term, and offer the possibility that the longer-term
outcomes may be improved through greater patient en-
gagement during treatment (although the latter clearly
requires empirical testing). We suggest that the next
step in better understanding the efficacy and efficiency
of HealthCall-S for drinking reduction in HIV-infected
patients is a larger randomized trial in conjunction with
a briefer, less skilled behavioral intervention in HIV pri-
mary care clinics.
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